One of our pharma clients was evaluating an investment into several AI and biomarker diagnostic solutions that could improve overall diagnosis rates for a rare disease.
We evaluated the client knowledge base of the disease area and patient journey across real-world data (RWD) and primary market insights. Our experts organized these insights within an opportunity assessment framework and identified key knowledge gaps. We also conducted qualitative HCP research to complete the assessment.
We developed strategic recommendations for our client around the opportunity assessment of these AI diagnostic technologies, which enabled the client to push forward with further investment.